PHIO
PHIO
NASDAQ · Biotechnology

Phio Pharmaceuticals Corp

$1.25
+0.05 (+4.17%)
Financial Highlights (FY 2025)
Revenue
2.43M
Net Income
150.5K
Gross Margin
41.2%
Profit Margin
6.2%
Rev Growth
+21.7%
D/E Ratio
0.76
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 41.2% 41.2% 41.2%
Operating Margin 8.4% 8.0% 9.6%
Profit Margin 6.2% 8.5% 8.4%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 2.43M 2.52M 2.31M
Gross Profit 1.00M 1.04M 954.1K
Operating Income 204.6K 202.9K 221.9K
Net Income 150.5K 215.1K 194.2K
Gross Margin 41.2% 41.2% 41.2%
Operating Margin 8.4% 8.0% 9.6%
Profit Margin 6.2% 8.5% 8.4%
Rev Growth +21.7% -7.9% -0.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 3.21M 3.29M 3.47M
Total Equity 4.23M 4.11M 4.07M
D/E Ratio 0.76 0.80 0.85
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 295.2K 302.7K 296.9K
Free Cash Flow 147.2K 165.8K 140.8K